Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route

Tuberculosis Clinical Trial

Official title:

Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01181856
• Other study ID #: TB022
• Status: Completed
• Phase: Phase 1
• First received: August 11, 2010
• Last updated: March 25, 2011
• Start date: January 2010
• Est. completion date: January 2011

Study information

• Verified date: March 2011
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This is a phase I study that will compare the safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route in healthy adult individuals who have been previously vaccinated with Bacillus Calmette-Guerin (BCG).

Description:

We postulate that the intramuscular route is not inferior to the intradermal route of administration of MVA85A in BCG vaccinated adults when evaluated for safety and immunogenicity.

If MVA85A can be given safely by intramuscular route and it is at least equally immunogenic and efficacious in a prime-boost strategy, then it would probably be the preferred route in subsequent phase II and III trials. There are several reasons for this:

• Reduced pain associated with injection.

• Reduced local reaction at the injection site.

• More straightforward procedure; less technically demanding; less time consuming.

• Easier production and storage of vaccine.

• Larger volume of vaccine can be given.

Trials of MVA85A to date have established 1 x 10^8 pfu as the optimal dose for intradermal injection in adults. We therefore intend to administer this same dose intramuscularly in order to directly compare the two routes for both safety and immunogenicity. These results will guide future trials in which the intramuscular route, if safe, could be further evaluated at either higher or lower dose depending on immunogenicity at 1 x 10^8 pfu dosage.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy adult aged 18 - 55 years (both male and female)

2. Resident in or near Oxford for the duration of the study period

3. Confirmation of prior vaccination with BCG not less than 3 months prior to projected study vaccination date (by visible BCG scar on examination or written documentation)

4. Normal medical history and physical examination

5. Willingness to allow the Investigators to discuss the individual's medical history with their GP

6. Willingness to use continuous effective barrier contraception for three months after receiving the vaccination (males and females)

7. Willingness to use effective contraception for the duration of the study period (females only)

8. Agreement to refrain from blood donation during the course of the study

9. Give written informed consent

10. Agreement to allow the Investigator to register volunteer details with a confidential database to prevent concurrent entry into clinical trials

11. Able and willing (in the Investigator's opinion) to comply with all the study requirements

Exclusion Criteria:

1. Clinical, radiological, or laboratory evidence of current active TB infection

2. Laboratory evidence at screening of latent TB infection as indicated by a positive ELISPOT test (greater than 17 sfc/million PBMC) in any ESAT6 peptide or CFP10 peptide poola

3. Previous vaccination with candidate vaccine MVA85A or another recombinant MVA vaccine

4. Clinically significant history of skin disorder, allergy, immunodeficiency (including human immunodeficiency virus [HIV]), cancer (except basal cell carcinoma [BCC] or carcinoma in situ [CIS]), cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse

5. History of serious psychiatric condition

6. Concurrent oral or systemic steroid medication or the use of other immunosuppressive agents

7. History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the study vaccine

8. Any clinically significant abnormality of screening blood or urine tests

9. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV antibodies

10. Female currently lactating, confirmed pregnancy or intention to become pregnant during study period

11. Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the study vaccine for 30 days prior to dosing with the study vaccine, or planned use during the study period

12. Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date

13. Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk or may influence the result of the study or may affect the volunteer's ability to participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• MVA 85A
Single injection of 1 x 108 pfu MVA85A

Locations

Country	Name	City	State
United Kingdom	Centre of Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	Safety data in both groups, as assessed by the frequency, incidence, and nature of adverse events (AEs) and serious adverse events (SAEs) during the study. Safety is measured throughout the 6 months follow up period, but specifically on the following days: 2, 7, 14, 28, 56, 84 and 168 and. Blood for safety testing is taken at Days 7 and 28.	6 months following vaccination	Yes
Secondary	Immunogenicity	Immunogenicity data in both groups. This will be obtained from exploratory immunological laboratory investigations on blood samples taken at screening, and throughout follow up. Immunogenicity is measured throughout the 6 months follow up period, but specifically on the following days: 2, 7, 14, 28, 56, 84 and 168.	6 months following vaccination	No